Colorectal Cancer
Conditions
Keywords
Huaier granule, colorectal cancer, capecitabine, recurrence and metastasis
Brief summary
This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer
Detailed description
It is expected to include 756 patients with colorectal cancer (CRC) who were diagnosed as stage II and underwent radical resection (R0) according to the CSCO colorectal cancer guidelines 2022 and met the criteria for cabetabine monotherapy in the study center from July 2024 to June 2026. The experimental group was treated with Huaier Granule monotherapy, and 378 patients were expected to be included; The control group was treated with capecitabine monotherapy, and 378 cases were expected to be included. Patients in the experimental group began using Huaier granules within 14 days-2 months after surgery. Patients in control group received capecitabine treatment, with one course of treatment every 3 weeks, for a total of 4-6 courses. Patients will be visited every 12 weeks (± 14 days) for the first two years after enrollment, and every 24 weeks (± 14 days) for the third year, until the end of the study, withdrawal from the study for any reason, or death, whichever occurs first.
Interventions
DRUGHuaier granule
Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
DRUGCapecitabine
Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
Sponsors
Huazhong University of Science and Technology
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old, regardless of gender. * It is diagnosed as colorectal cancer by histopathology, TNM stage Ⅱ. * Received radical resection of colorectal cancer (R0) within 12 weeks prior to enrollment. * Not receiving neoadjuvant therapy before surgery, and not receiving any adjuvant therapy after surgery. * ECOG score 0-2 points. * According to the CSCO Colorectal Cancer Guidelines 2022, it meets the criteria for receiving monotherapy adjuvant therapy with capecitabine. * Clear consciousness, language expression or reading ability, able to communicate normally, and cooperate in completing questionnaire assessments. * Voluntarily join this study and sign an informed consent form.
Exclusion criteria
* Low rectal cancer (occurring within 12 centimeters from the anal margin) * Combining medical history of other malignant tumors. * Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (only in the experimental group). * Inability to take orally medication (experimental group, control group with oral medication included in standard treatment plan). * Pregnant or lactating women or planned pregnancy preparation. * In the past one month, the subjects have received Huaier granules or traditional Chinese patent medicines and simple preparations with similar efficacy or indications to Huaier granules (such as compound cantharides capsules, cinobufacin capsules, Kangai injection, Pingxiao tablets, please refer to the instruction manual for details). * Refusal to cooperate with follow-up. * Other reasons leading to the researcher's belief that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year disease-free survival rate (DFS) | start of treatment until 3-year follow-up | The proportion of surviving patients who did not experience disease recurrence or metastasis within 3 years after R0 surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1-year disease-free survival rate (DFS) | start of treatment until 1-year follow-up | The proportion of surviving patients who did not experience disease recurrence or metastasis within 1 years after R0 surgery. |
| 2-year disease-free survival rate (DFS) | start of treatment until 2-year follow-up | The proportion of surviving patients who did not experience disease recurrence or metastasis within 2 years after R0 surgery. |
| Overall survival (OS) | start of treatment until 3-year follow-up | The time from randomization and enrollment on the day of the patient to death for any reason. |
| The incidence and severity of adverse events (AE) and severe adverse events (SAE) | start of treatment until 3-year follow-up | The definition and severity grading of AE and SAE refer to the corresponding descriptions in the definition and evaluation section of adverse events, and the incidence rate is defined as the proportion of patients with AE and SAE to the corresponding total population. |
| The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR) | start of treatment until 3-year follow-up | The definition and severity grading of ADR, severe ADR, and SUSAR refer to the corresponding descriptions in the definition and evaluation section of adverse events. The incidence rate is defined as the proportion of patients with ADR, severe ADR, and SUSAR to the corresponding total population. |
| Quality of Life Score | baseline period and start of treatment until 3-year follow-up | Evaluation using the EORTC QLQ-C30 (Chinese version) core quality of life scale developed by the European Organization for Cancer Research and Treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference) | start of treatment until 3-year follow-up | The difference in carcinoembryonic antigen levels between the treatment and baseline periods. |
Countries
China
Contacts
Primary ContactSanjun Cai, PhD
Backup ContactFangqi Liu, PhD
Outcome results
None listed